Inhibrx Biosciences (INBX) Interest Coverage Ratio (2023 - 2026)

Inhibrx Biosciences (INBX) posted quarterly Interest Coverage Ratio of 9.68 for Q4 2025, down 128.67% quarter-over-quarter from 4.23 in Q3 2025.

Analysis

Inhibrx Biosciences (INBX) Interest Coverage Ratio (2023 - 2026) Analysis & Trends

Inhibrx Biosciences (INBX) has reported Interest Coverage Ratio for 3 consecutive years, with 9.68 the latest figure, recorded in Q4 2025.

In Q4 2025, Interest Coverage Ratio changed N/A year-over-year to 9.68; the TTM figure through Dec 2025 stood at 15.71 (up 35.88% YoY), while the FY2025 annual figure was 0.61, up 95.97% from the prior year.
Interest Coverage Ratio retreated to 9.68 in Q4 2025 per INBX's latest filing, from 4.23 in the prior quarter.
Across five years, Interest Coverage Ratio topped out at 3.15 in Q2 2025 and bottomed at 29.8 in Q2 2024.
Historically, Interest Coverage Ratio has averaged 11.08 across 3 years, with a median of 5.62 in 2023.
Annual changes were most pronounced in 2024 — Interest Coverage Ratio tumbled 469.77% — and 2025, when it jumped 89.43%.
Inhibrx Biosciences' Interest Coverage Ratio stood at 28.32 in 2023, then decreased by 5.19% to 29.8 in 2024, then soared by 67.53% to 9.68 in 2025.
Business Quant data shows INBX's Interest Coverage Ratio at 9.68 in Q4 2025, 4.23 in Q3 2025, and 3.15 in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Cover (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	117.59
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-493.00
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-21.24
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	8.18
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	2.82
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	1.42
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.08
10	Inhibrx Biosciences	1.91 Bn	1.91 Bn	-	-5.65

Historic Data

Download Data